It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback